Exercise-Induced Gut Permeability in Normal-weight Obesity

Oklahoma State University

Status: Enrolling

Conditions: Obesity; Normal-weight Obesity

Treatments: Other: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)

Study type: Interventional

Funder types: Other

Identifiers

NCT05889767

IRB-22-28-STW

Details and patient eligibility

About

Exercise acutely increases gut permeability and inflammation, even in healthy populations. However, whether this response differs in groups at-risk for CVD that present with low-grade inflammation (e.g., normal-weight obesity) has yet to be examined. The investigators aim to measure serum indicators of gut permeability in those with normal-weight obesity pre- and post-short, intense exercise and sustained, moderate exercise

Full description

The investigator's overall goal is to examine how indicators of gut permeability change in response to exercise in individuals with normal-weight obesity (i.e., normal body mass index [BMI] and high body fat percent) relative to those with a normal BMI and low body fat percent and those with a BMI in the obesity range and high body fat percent.

The investigators will examine indicators of gut permeability (specified in primary outcomes) in response to a short, intense bout of exercise (i.e., VO2 max test on a cycle ergometer) and sustained, moderate bout of exercise (i.e., 45 minutes at 65% measured VO2 max on a cycle ergometer).

Additionally, the investigators will measure basic anthropometrics, blood lipids and glucose, and body composition with DXA.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Control group: normal BMI, body fat percentage < 25% (male) or < 35% (female)

Normal-weight obesity: normal BMI, body fat percentage > 25% (male) or > 35% (female)

Overt obesity: BMI in obesity range, body fat percentage > 25% (male) or > 35% (female)

Exclusion criteria

• Presence of pacemaker
• Pregnant
• Postmenopausal status
• History of chronically using of tobacco products, illicit drugs, anti-inflammatory drugs (e.g., NSAIDs), lipid lowering drugs
• Recent use of antibiotics (< 6 weeks) and NSAIDs (< 3 days)
• Established cardiometabolic disease (e.g., cardiovascular disease, type 2 diabetes) diseases inflammatory in nature (e.g., rheumatoid arthritis, inflammatory bowel disease), and/or diagnosed irritable bowel syndrome.

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

30 participants in 3 patient groups

Normal weight and low body fat percent

Active Comparator group

Description:

The low risk comparator group for this study will consist of individuals with normal BMI (18.5 - 24.9 kg/m2) and body fat percent \< 25% (male) or \< 35% (female).

Treatment:

Other: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)

Normal-weight obesity

Experimental group

Description:

Individuals with normal-weight obesity will be defined as having normal BMI (18.5 - 24.9 kg/m2), body fat percent \> 25% (male) or \> 35% (female).

Treatment:

Other: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)

Overt obesity and high body fat percent

Active Comparator group

Description:

Overt obesity (BMI \> 30 kg/m2) with high body fat percent (\> 25% \[male\] or \> 35% \[female\]) will be used as a high-risk comparator group.

Treatment:

Other: Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)